Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection

Clinical Microbiology and Infection

Volumn 21, Issue 5, 2015, Pages 493.e1-493.e4

  Russo, A ^a   Falcone, M ^a   Fantoni, M ^b   Murri, R ^b   Masucci, L ^b   Carfagna, P ^c   Ghezzi, M C ^a   Posteraro, B ^d   Sanguinetti, M ^b   Venditti, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^c 'San Giovanni Addolorata' Hospital   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

Author keywords

Candida bloodstream infection; Candida colonization; Clostridium difficile infection; Oral vancomycin; Ribotype 027

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CANDIDEMIA; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL BASED CASE CONTROL STUDY; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MALE; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; CASE CONTROL STUDY; CLASSIFICATION; CLOSTRIDIUM INFECTIONS; COMPLICATION; ENTEROCOLITIS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; RIBOTYPING; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

CANDIDA; CLOSTRIDIUM DIFFICILE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CANDIDEMIA; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBOTYPING; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84930511264     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2014.12.024     Document Type: Article

References (16)

1. Nerandzic M.M., Mullane K., Miller M.A., Babakhani F., Donskey C.J. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012, 55:S121-S126.
2. Guastalegname M., Russo A., Falcone M., Giuliano S., Venditti M. Candidemia subsequent to severe infection due to Clostridium difficile: is there a link?. Clin Infect Dis 2013, 57:772-774.
3. Guastalegname M., Grieco S., Giuliano S., Falcone M., Caccese R., Carfagna P., et al. A cluster of fulminant Clostridium difficile colitis in an intensive are unit in Italy. Infection 2014, 42:585-589.
4. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-332.
5. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
6. Li J.S., Sexton D.J., Mick N., Nettles R., Fowler V.G., Ryan T., et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000, 30:633-638.
7. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of Americ (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America.
8. Spigaglia P., Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 2002, 40:3470-3475.
9. Raponi G., Visconti V., Brunetti G., Ghezzi M.C. Clostridium difficile infection and Candida colonization of the gut: is there a correlation?. Clin Infect Dis 2014 Aug 4, 59:1648-1649.
10. Warren C.A., van Opstal E.J., Riggins M.S., Li Y., Moore J.H., Kolling G.L., et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother 2013, 57:689-696.
11. Madan R., Petri W.A. Immune responses to Clostridium difficile infection. Trends Mol Med 2012, 18(11):658-666.
12. Nam H.J., Kang J.K., Kim S.K., Ahn K.J., Seok H., Park S.J., et al. Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation. J Biol Chem 2010, 22(285):32888-32896.
13. Chumbler N.M., Farrow M.A., Lapierre L.A., Franklin J.L., Haslam D.B., Goldenring J.R., et al. Clostridium difficile toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog 2012, 8(12).
14. Brito G.A., Sullivan G.W., Ciesla W.P., Carper H.T., Mandell G.L., Guerrant R.L. Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function. J Infect Dis 2002, 185:1297-1306.
15. Di Bella S., Paglia M.G., Johnson E., Petrosillo N. Clostridium difficile 027 infection in Central Italy. BMC Infect Dis 2012, 22(12):370.
16. Orsi G.B., Conti C., Mancini C., Giordano A. Clostridium difficile 027 increasing detection in a teaching hospital in Rome, Italy. Infection 2014, 42:941-942.